A phase II placebo-controlled crossover trial of subcutaneous avexitide at two doses (30 mg twice a day and 60 mg once a day) over 28 days in 18 people with PBH showed improvements in nadir glucose and peak insulin during an OGTT, reduction in hypoglycaemia without relevant increases in hyperglycaemia on CGM, and improvements in rates of hypoglycaemia defined as self-measured blood glucose (SMBG) <70 mg/dL (3.9 mmol/L), <54 mg/dL (3.0 mmol/L) and severe hypoglycaemic events with altered mental and/or physical function requiring assistance (110). This evidence concerns the gene INS and Hypoglycemia.